Holen Sie sich die Stockscreener-App
20.88
4.23%
-0.8906
Schlusskurs vom Vortag:
$21.77
Offen:
$21.62
24-Stunden-Volumen:
1.12M
Relative Volume:
0.25
Marktkapitalisierung:
$1.30B
Einnahmen:
$14.34M
Nettoeinkommen (Verlust:
$-199.00M
KGV:
-5.3264
EPS:
-3.92
Netto-Cashflow:
$-183.51M
1W Leistung:
-17.65%
1M Leistung:
-24.97%
6M Leistung:
+23.37%
1J Leistung:
+185.81%
1-Tages-Spanne:
$20.63
$21.75
1-Wochen-Bereich:
$20.55
$25.79
52-Wochen-Spanne:
$7.76
$71.50
Uniqure N V Stock (QURE) Company Profile
Firmenname
Uniqure N V
Sektor
Branche
Telefon
1-339-970-7000
Adresse
PAASHEUVELWEG 25A, AMSTERDAM
Vergleichen Sie QURE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
20.86 | 1.36B | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.76 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.23 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.46 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
893.54 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
194.12 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-04 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-04-01 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2024-12-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-02-29 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-17 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-11-09 | Eingeleitet | Jefferies | Buy |
| 2020-11-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-08-25 | Eingeleitet | Raymond James | Strong Buy |
| 2020-07-31 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-06-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Eingeleitet | Cowen | Outperform |
| 2019-12-03 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | Credit Suisse | Outperform |
| 2019-10-11 | Eingeleitet | Stifel | Buy |
| 2019-09-25 | Eingeleitet | Bernstein | Outperform |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-07-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-07-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Uniqure N V Aktie (QURE) Neueste Nachrichten
Mizuho Lowers Price Target for uniQure (QURE) to $33.00 | QURE S - GuruFocus
Mizuho Securities Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $33 - 富途牛牛
Swiss National Bank Makes New Investment in uniQure N.V. $QURE - MarketBeat
Notice of Investigation of QURE: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - GlobeNewswire Inc.
Voss Capital LP Takes $1.74 Million Position in uniQure N.V. $QURE - MarketBeat
Pale Fire Capital SE Boosts Stake in uniQure N.V. $QURE - MarketBeat
7 Hidden Multibagger Stocks to Invest In - Insider Monkey
Progress on AMT-130 Halts uniQure N.V.’s (QURE) Downtrend - Insider Monkey
Aug Wrap: Can uniQure NV stock surprise with earnings upside2025 Key Highlights & Smart Swing Trading Techniques - BỘ NỘI VỤ
uniQure (NASDAQ:QURE) Shares Down 5.1%Here's What Happened - MarketBeat
QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - Your Wyoming Link
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
uniQure (NASDAQ:QURE) Receives "Buy" Rating from Chardan Capital - MarketBeat
uniQure (NASDAQ:QURE) Shares Gap DownHere's What Happened - MarketBeat
How uniQure N.V. (UQ1) stock benefits from digital adoptionTrade Ideas & Scalable Portfolio Growth Methods - Newser
How strong is uniQure N.V. stock revenue growthJuly 2025 Sentiment & Scalable Portfolio Growth Ideas - Newser
uniQure (QURE) Is Down 17.3% After FDA Questions AMT-130 Data Sufficiency For BLAHas The Bull Case Changed? - simplywall.st
Chardan Capital Maintains uniQure N.V. (QURE) Buy Recommendation - Nasdaq
QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Enc - GuruFocus
uniQure (QURE) Stock: Navigates Regulatory Hurdles for AMT-130 as FDA Requests Further Engagement - parameter.io
uniQure (QURE) Analyst Ratings: Chardan Capital Maintains Buy Ra - GuruFocus
Why uniQure Stock Is Trading Lower After FDA Meeting Update - Benzinga
uniQure N.V. (QURE): A Bear Case Theory - Finviz
uniQure (QURE) Shares Plunge 20% on FDA Feedback for AMT-130 - GuruFocus
uniQure says FDA announced Phase I/II AMT-130 data unlikely to support BLA - TipRanks
uniQure stock falls after FDA signals data unlikely to support AMT-130 approval - Investing.com Australia
UniQure stock falls after FDA's notes on pre-application of AMT-130 - MSN
uniQure stock falls after FDA's notes on pre application of AMT-130 - Seeking Alpha
uniQure (QURE) Reassesses Strategy After FDA Feedback on AMT-130 Application - GuruFocus
UniQure Seeks US FDA Follow-Up Meeting After Being Told Data Do Not Support BLA Submission - marketscreener.com
Why Is UniQure Stock Falling In Pre-market? - Nasdaq
uniQure Faces Setback in Gene Therapy Approval - TipRanks
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease - The Manila Times
uniQure N.V. Provides Regulatory Update on AMT-130 for Huntington's Disease - TradingView
Uniqure N.V. Provides Regulatory Update on Amt-130 for Huntington's Disease - marketscreener.com
uniQure (NASDAQ: QURE) receives FDA minutes on AMT-130 BLA path for Huntington’s disease - Stock Titan
uniQure N.V. $QURE Stake Reduced by Schroder Investment Management Group - MarketBeat
uniQure N.V. $QURE Shares Acquired by JPMorgan Chase & Co. - MarketBeat
(QURE) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
uniQure N.V. (UQ1) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Smart Money Is Betting Big In QURE Options - Benzinga
Can uniQure N.V. stock sustain institutional interestDip Buying & Stock Portfolio Risk Management - Newser
Will uniQure N.V. (UQ1) stock draw ESG focused fundsQuarterly Growth Report & Long-Term Capital Growth Ideas - Newser
QURE Investigation: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
How uniQure N.V. stock performs in weak economy2025 Stock Rankings & AI Forecasted Stock Moves - Newser
Will uniQure N.V. (UQ1) stock sustain uptrend momentumJuly 2025 Momentum & Community Consensus Picks - Newser
Can uniQure N.V. (UQ1) stock sustain revenue momentumWeekly Profit Report & Detailed Earnings Play Strategies - Newser
uniQure (QURE) Surges 17.9% Ahead of 2 Health Conferences - MSN
ETF Watch: How strong is uniQure NV stock revenue growthJuly 2025 Rallies & Stock Portfolio Risk Management - BỘ NỘI VỤ
Wall Street Zen Upgrades uniQure (NASDAQ:QURE) to Hold - MarketBeat
uniQure N.V. (QURE) Options Chain - Yahoo! Finance Canada
Finanzdaten der Uniqure N V-Aktie (QURE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Uniqure N V-Aktie (QURE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gut Robert | Director |
Nov 06 '25 |
Sale |
27.26 |
31,434 |
856,881 |
40,145 |
| Kaye Jack | Director |
Nov 04 '25 |
Option Exercise |
9.88 |
38,810 |
383,535 |
38,249 |
| Kaye Jack | Director |
Nov 04 '25 |
Sale |
30.34 |
38,810 |
1,177,517 |
20,439 |
1.37%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):